ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 190.7 DKK 1.44% Market Closed
Market Cap: 38.6B DKK

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 224.05 DKK. Compared to the current market price of 190.7 DKK, ALK-Abello A/S is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
224.05 DKK
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
25
vs Industry
23
Median 3Y
6
Median 5Y
6.5
Industry
2.5
Forward
6.6
vs History
73
vs Industry
11
Median 3Y
50.2
Median 5Y
57.1
Industry
21.8
Forward
37.4
vs History
74
vs Industry
16
Median 3Y
39.7
Median 5Y
46.5
Industry
16.6
vs History
23
vs Industry
3
Median 3Y
88.4
Median 5Y
80.8
Industry
24
vs History
34
vs Industry
12
Median 3Y
6.3
Median 5Y
6.8
Industry
2.1
vs History
25
vs Industry
22
Median 3Y
6
Median 5Y
6.5
Industry
2.7
Forward
6.6
vs History
31
vs Industry
24
Median 3Y
9.5
Median 5Y
10.1
Industry
5.3
vs History
55
vs Industry
16
Median 3Y
27.3
Median 5Y
29.4
Industry
12.8
Forward
21.9
vs History
65
vs Industry
16
Median 3Y
36.6
Median 5Y
40.4
Industry
16.2
Forward
26.5
vs History
76
vs Industry
17
Median 3Y
40.7
Median 5Y
47
Industry
15.1
vs History
0
vs Industry
6
Median 3Y
173.6
Median 5Y
173.6
Industry
17.7
vs History
20
vs Industry
18
Median 3Y
4.5
Median 5Y
4.8
Industry
1.9

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
42.3B DKK 7.4 45.1 27.7 33.9
US
Eli Lilly and Co
NYSE:LLY
743.2B USD 15.2 67 35.9 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 4.2 17.2 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.8 13 14.9
CH
Roche Holding AG
SIX:ROG
206B CHF 3.4 24.9 9.4 10.9
CH
Novartis AG
SIX:NOVN
191.1B CHF 4.5 18.7 11 14.7
UK
AstraZeneca PLC
LSE:AZN
160.7B GBP 4 28.1 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
211B USD 3.3 12.1 9 10.9
IE
Endo International PLC
LSE:0Y5F
185.4B USD 79.9 -63.4 294.8 739.4
US
Pfizer Inc
NYSE:PFE
144.5B USD 2.3 18.3 7.8 11
P/E Multiple
Earnings Growth PEG
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 27.8
45.1
23%
2
US
Eli Lilly and Co
NYSE:LLY
67
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.4 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 399.8
27.7
21%
1.3
US
Eli Lilly and Co
NYSE:LLY
35.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 708.3
33.9
23%
1.5
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.7
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.9
11%
1
IE
E
Endo International PLC
LSE:0Y5F
739.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1